Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the recipient of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 1,060,000 shares, a decrease of 23.7% from the February 13th total of 1,390,000 shares. Based on an average trading volume of 92,200 shares, the days-to-cover ratio is presently 11.5 days. Approximately 13.5% of the company’s stock are short sold.

Karyopharm Therapeutics Stock Performance

Shares of Karyopharm Therapeutics stock traded down $0.31 during trading on Tuesday, hitting $5.83. 199,622 shares of the company’s stock were exchanged, compared to its average volume of 74,152. The stock has a market capitalization of $49.09 million, a price-to-earnings ratio of -5.72 and a beta of 0.11. The business has a 50-day simple moving average of $8.93 and a 200-day simple moving average of $10.79. Karyopharm Therapeutics has a 52-week low of $5.58 and a 52-week high of $24.75.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.90) by $0.30. The company had revenue of $30.54 million for the quarter, compared to analysts’ expectations of $30.29 million. On average, equities analysts anticipate that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on KPTI shares. HC Wainwright upped their price target on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday, February 26th. StockNews.com downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Royal Bank of Canada reiterated an “outperform” rating and set a $45.00 price target on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. Finally, Robert W. Baird cut their price objective on Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Karyopharm Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Velan Capital Investment Management LP acquired a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at $27,000. Focus Partners Wealth acquired a new position in shares of Karyopharm Therapeutics in the fourth quarter worth about $31,000. TD Waterhouse Canada Inc. purchased a new stake in shares of Karyopharm Therapeutics during the 4th quarter worth about $32,000. Two Sigma Advisers LP grew its position in shares of Karyopharm Therapeutics by 145.5% during the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after acquiring an additional 45,400 shares during the period. Finally, Opti Capital Management LP acquired a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at about $85,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).